Dr. Don Stewart is an entrepreneur and scientist with more than 20 years of management experience in the biotechnology industry. Dr. Stewart served as Director Research of Cangene Corporation from 1997 to 2007. At Cangene, he led programs to develop monoclonal antibodies and recombinant protein drugs and obtained more than $15 million in external grant and contract funding over a five-year period. Dr. Stewart has a PhD in biochemistry from the U

Mr. Hosking is a chartered accountant with three decades of experience as a financial manager in the biotechnology and pharmaceutical industries. From 1997 to 2008, Mr. Hosking was Vice-President Finance & Chief Financial Officer for PreMD Inc., a developer of point-of-care medical devices. He guided the company through seven public financings and onto the TSX (2000) and AMEX (2002) stock exchanges. He also helped negotiate out-licensing partner

Dr. Chris Hall is a professor and Canada Research Chair in Recombinant Antibody Technology at the University of Guelph. As a Tier 1 Canada Research Chair since 2002, Dr. Hall is acknowledged as a world leader in his field. His research focuses on producing antibodies from plants (instead of animals) for a range of applications, including human immunotherapy. Dr. Hall's research group also studies the large-scale production of antibodies in plant

Mr. David Cayea is an entrepreneur with more than 14 years of experience in the successful start-up of private sector companies in multiple industries. He has extensive business management experience in Europe, Asia and North America, most recently as the founder and CEO of North American Safety Consultants, based in Abu Dhabi, United Arab Emirates. David has a Bachelor of Arts degree from Brock University in Environmental Studies and Politics as